LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab (TA) versus placebo + atezolizumab (PA) as first-line treatment for PD-L1+ NSCLC

B.C. Cho, Delvys Rodríguez‐Abreu, Maen Hussein, Manuel Cobo, A. Patel, Nevena Sečen, Gregory J. Gerstner, Dongwook Kim, Y-G. Lee, Wu‐Chou Su, E.P. Huang, Namrata S. Patil, Mo Huang, Z. Zhang, X. Wen, Diana Mendus, Tien Hoang, Robin Meng, Melissa L. Johnson